Invicro LLC

LONDON and BOSTON, June 7, 2024 /PRNewswire/ -- Calyx / Invicro, a global leader in providing medical imaging solutions and development services to the clinical research community, today announces a strategic partnership with BAMF Health, a world leader in molecular imaging and theranostics. The partnership aims to accelerate the clinical translation of radioligand therapies (RLT) and immuno-oncology (IO) agents. Continue Reading Calyx / Invicro COO Edward Hogan believes the partnership with BAMF Health will bring the same innovation and acceleration to oncology as the organization’s translational model has demonstrated in the CNS field. Invicro BAMF Health is leveraging its GE HealthCare StarGuide™ SPECT/CT to usher in a new era of discovery in Nuclear Medicine. This advanced system, integral to our partnership, provides accurate quantitation, empowering clinicians to make personalized care decisions and assess treatment responses with precision, ensuring faster and more efficient development of radioligand and immuno-oncology therapies for our customers. BAMF Health

Five research teams have been granted $9.75 million in total funding through The Michael J. Fox Foundation's ongoing efforts to validate quantitative biomarkers for Parkinson's disease All funded teams aim to produce "quantitative" biomarkers, which measure and track the progression of PD through biology, to be ready for use in drug trials within two to three years Quantitative biomarkers would improve drug trials, especially those testing therapies to slow or stop the progression of PD, by giving specific, objective measures tied to disease progression NEW YORK, May 30, 2024 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced today $9.75 million in total awards to five research teams working on tools to biologically measure and track the progression of Parkinson's disease (PD) from its earliest detection through more advanced stages. Collectively referred to as "quantitative" biomarkers, these tools would improve clinical trials with clear, objective measures. Parkinson's trials have historically relied on subjective assessments to judge the speed at which a person's PD is progressing. Those assessments come from clinician observations or trial participants filling out surveys noting their symptoms, but they can be inconsistent based on the visit, clinician or person. These inconsistencies make it difficult to clearly judge whether a therapy is effectively helping the individual living with disease. To objectively test if a therapy can slow or stop the progression of Parkinson's and bring functional benefit to patients, we need validated and reliable tools to measure the biology associated with that progression. Current biomarker-based approaches do not provide the level of detail needed to assess the effect of a given therapy. The biomarker test that was validated last year, the alpha-synuclein seeding amplification assay (aSyn SAA), is binary, meaning it shows whether or not the signature misfolded protein in PD (alpha-synuclein, or aSyn) is present. It does not reveal how much of the protein is present or whether the amount is increasing or decreasing over time. In contrast, quantitative biomarkers would be capable of providing specific measurements related to disease progression, equipping clinical trial researchers with powerful indicators of whether an experimental treatment is having an effect. "Our Foundation exists to accelerate the development of better treatments for people with Parkinson's, and better treatments come from better clinical trials. Quantitative biomarkers would empower these trials in a significant way, giving us our best view yet of a treatment's efficacy," said Todd Sherer, PhD, MJFF's chief mission officer. "The projects announced today aim to fast-track clinical trial science to move us meaningfully closer to our goal of curing Parkinson's disease." Funded Research Projects for Quantitative Biomarkers The quantitative biomarker funding goes to researchers developing some of the most promising tools to biologically detect, measure and track the progression of PD. Five research teams received support for their work. MJFF continues to review applications and plans to award funding to additional teams by the end of 2024. Notably, all of the funded projects hold potential to deliver clinical trial-ready quantitative biomarker tests within the next two to three years, just when many of the therapies in the Parkinson's pipeline currently could reach Phase III testing, a crucial juncture for drug makers needing to determine a therapy's effectiveness. Biochemical biomarker research projects Three of the funded research teams are focused on developing reliable, lab-based tests to measure the amount of misfolded aSyn in readily available biosamples, including skin and blood. They include: Kalpana Merchant, PhD, will lead a consortium of groups focused on blood-based SAA, collaborating with Daniela Berg, MD, at University Hospital Schleswig-Holstein Kiel, Nobutaka Hattori, MD, PhD, at Juntendo University, Johan Skog, PhD, at Exosome Diagnostics, Erez Eitan, PhD, at NeuroDex, Anton Iliuk, PhD, with Tymora Analytics and Luis Concha, PhD, at Amprion in leading an effort to validate a blood-based quantitative biomarker for SAA. A team co-led by Concha and Tatiana Foroud, PhD, at Indiana University is working to validate a skin-based quantitative biomarker from SAA. Tuomas Knowles, PhD, and his lab at Cambridge University are developing microfluidics-based technology to improve the speed of SAA testing, which is currently conducted in spinal fluid, and make it quantitative. Imaging research projects Two funded research teams are developing imaging tools to detect clumps of aSyn in the brain, using positron emission tomography (PET) imaging technology. They include: David Russell, MD, PhD, from Invicro with the support of Makoto Higuchi, MD, PhD, are heading up a collaboration between the National Institute of Radiological Sciences in Japan and Invicro to develop a tool to visualize aSyn in the brain and track how it changes over time. Led by Helen Mitchell, PhD, and Eric Hostetler, PhD, Merck is developing its own tool to visualize aSyn in the brain and track how it changes over time in PD. The Merck team was last year's winner of MJFF's Ken Griffin Alpha-synuclein Imaging Competition. The $10-million competition — funded by a leadership gift from Ken Griffin, founder and CEO of Citadel and founder of Griffin Catalyst — launched in 2019 in pursuit of an imaging tracer to visualize misfolded aSyn in the living brains of people with PD. This scientific race helped catapult biomarker research forward. Details on the funded studies, including grant abstracts and researcher bios, are available on the Foundation's website, . About The Michael J. Fox Foundation for Parkinson's Research (MJFF) As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $2 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open-access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at , Facebook or Twitter. SOURCE The Michael J. Fox Foundation for Parkinson's Research

BOSTON, April 2, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointments of Bill Cupelo as the company's Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors. These strategic additions to Ratio's leadership team will further advance Ratio's growth and innovation in the development and commercialization of radiopharmaceuticals for cancer diagnosis and treatment. "We are pleased to welcome Bill Cupelo and D. Scott Holbrook to the Ratio team," commented Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio. "These appointments underscore our commitment to building a leadership team that will propel us forward in advancing our radiopharmaceutical platforms. Mr. Cupelo's proven track record of success in business development and strategy will be instrumental in accelerating our growth and building out our pipeline of novel therapeutics and diagnostics. In addition, Mr. Holbrook's expertise in enabling the transition of innovative precision medicine technologies from experimental stages to practical application in clinical environments will be an invaluable addition to our board." "I am honored to join Ratio at such a pivotal time, as the development of targeted radiopharmaceuticals continues to build momentum in our industry," said Bill Cupelo, Chief Business Officer of Ratio. "The company's recent $50M Series B financing puts them in an excellent position to advance their first FAP-targeted therapeutic candidate into the clinic this year. I look forward to leveraging my experience to advance business development and drive strategic growth initiatives, ensuring that Ratio's innovative radiopharmaceuticals reach the patients who need them the most." Mr. Cupelo brings a sponsor and science-first mindset with over 10 years' experience in sales with a focus on oncology and neurology. Prior to joining Ratio, Mr. Cupelo was Head of Sales at Invicro, where he was responsible for all sales operations and account relations with a focus on clinical imaging core lab, software informatics, and data science products and services as well as strategic alliances with pharma partners. Previously, Mr. Cupelo also served as Vice President of Business Development and Strategic Accounts, and Software Product Manager at Invicro. Mr. Cupelo holds an MS in Biotechnology from Georgetown University and a BS in Chemistry from the College of the Holy Cross. "I am impressed with the strength of Ratio's platform and look forward to the opportunity to work alongside my Board colleagues to help guide the company's growth and development," said D. Scott Holbrook. "I am eager to apply my experience in radiopharmaceutical manufacturing and supply chain solutions to help Ratio accelerate the development and future commercialization of its targeted radiopharmaceuticals for cancer therapy." Mr. Holbrook joins Ratio's Board of Directors with 25+ years of experience in the field of molecular imaging and therapeutics, which encompasses all phases of radiopharmaceutical drug development including target identification, GMP manufacturing, quality and regulatory matters, clinical trials, translation, post-approval manufacturing and imaging. He currently serves as the General Manager and Chief Strategy Officer of PharmaLogic, where he is responsible for guiding the strategic direction and implementation of diagnostic and therapeutic drug products. Mr. Holbrook holds an MS in Molecular Imaging and Therapeutics from Regis College and a BS in Nuclear Medicine Technology from Wheeling Jesuit University. About Ratio Therapeutics Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, TrilliumTM and MacropaTM, enable the development of tunable radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. Ratio, in collaboration with Lantheus and PharmaLogic, is currently conducting a Phase I trial to evaluate the efficacy of a novel fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers in adult healthy volunteers. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year. Please visit for more information and follow us on Twitter (X) and LinkedIn. Media Contact: Rachelle Babb, Ph.D. Russo Partners, LLC [email protected] +1 (929) 325-7559 SOURCE Ratio Therapeutics Inc.